Last reviewed · How we verify
Pharmacotherapy to slow and control ventricular rate
The drug, developed by the National Institute of Cardiology in Warsaw, Poland, is a marketed pharmacotherapy designed to slow and control ventricular rate. A key strength is the protection afforded by its composition patent, which expires in 2028. The primary risk is the lack of disclosed revenue data, which may limit insights into its commercial performance.
At a glance
| Generic name | Pharmacotherapy to slow and control ventricular rate |
|---|---|
| Also known as | beta-blockers, digitalis, amiodarone |
| Sponsor | National Institute of Cardiology, Warsaw, Poland |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |